HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

biotech

First precision therapy prostate cancer drug approved

Jim Cornall - December 17, 2025

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Basel life sciences supercluster welcomes Korean biopharmas

biotech

Study shows IL-23 inhibitor demonstrates efficacy in perianal fistulizing Crohn’s disease

biotech

Hand-held probe maps cancerous tissue

biotech

Cells “back up” DNA replication to survive damage

biotech

Base to Base biotech podcast 58: Congenital myotonic dystrophy